Suppr超能文献

甲胎蛋白/白蛋白和中性粒细胞与淋巴细胞比值对接受 TACE 和 RFA 治疗的肝细胞癌患者的预后意义。

Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA.

机构信息

Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

Department of Gynecology, Wangjing Hospital of Chinese Academy of Chinese Medical, Beijing, China.

出版信息

J Clin Lab Anal. 2019 Nov;33(9):e22999. doi: 10.1002/jcla.22999. Epub 2019 Aug 16.

Abstract

BACKGROUND

The C-reactive protein (CRP)/albumin (Alb) ratio (CAR) is a basic inflammatory factor that has been related to poor survival of patients with various tumors. Our research retrospectively examined the relationship between the CAR and the prognosis of hepatocellular carcinoma (HCC).

METHODS

This study included 172 patients with HCC who were treated with transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA).

RESULTS

The CAR was weakly related to the neutrophil/lymphocyte ratio (NLR, r = .159, P = .037) and the lymphocyte/monocyte ratio (LMR, r = -.263, P = .001). The Glasgow Prognostic Score (GPS) (0/1-2) was related to liver cirrhosis (P = .003), tumor number (P = .02), Child-Pugh grade (P = .001), the platelet/lymphocyte ratio (PLR, P = .006), and the LMR (P = .021). Correlation analysis demonstrated that an elevated CAR was markedly correlated with the tumor size (P = .019), alpha-fetoprotein (AFP) level (P = .033), thrombosis of the portal vein (P = .004), the NLR (P = .036), and the LMR (P = .001). Multivariate analysis indicated that the prognosis of the CAR-High and NLR-High cohort (mOS = 7 months) was significantly worse than those of the CAR-High or NLR-High cohort (mOS = 15 months) and the CAR-Low and NLR-Low cohort (mOS = 26.5 months).

CONCLUSIONS

Combination of the NLR and the CAR represents a convenient, quick, and noninvasive biological marker that could improve prognostic prediction in patients with HCC.

摘要

背景

C 反应蛋白(CRP)/白蛋白(Alb)比值(CAR)是一种基本的炎症因子,与各种肿瘤患者的不良预后相关。我们的研究回顾性检查了 CAR 与肝细胞癌(HCC)预后之间的关系。

方法

本研究纳入了 172 例接受经导管动脉化疗栓塞(TACE)和射频消融(RFA)治疗的 HCC 患者。

结果

CAR 与中性粒细胞/淋巴细胞比值(NLR,r =.159,P =.037)和淋巴细胞/单核细胞比值(LMR,r =.263,P =.001)呈弱相关。格拉斯哥预后评分(GPS)(0/1-2)与肝硬化(P =.003)、肿瘤数量(P =.02)、Child-Pugh 分级(P =.001)、血小板/淋巴细胞比值(PLR,P =.006)和 LMR(P =.021)相关。相关性分析表明,CAR 升高与肿瘤大小(P =.019)、甲胎蛋白(AFP)水平(P =.033)、门静脉血栓形成(P =.004)、NLR(P =.036)和 LMR(P =.001)显著相关。多因素分析表明,CAR 高和 NLR 高组(mOS = 7 个月)的预后明显差于 CAR 高或 NLR 高组(mOS = 15 个月)和 CAR 低和 NLR 低组(mOS = 26.5 个月)。

结论

NLR 和 CAR 的联合是一种方便、快速、无创的生物标志物,可以改善 HCC 患者的预后预测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90ba/6868405/43edf1fc69ae/JCLA-33-na-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验